| Q36070770 | A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer |
| Q64111238 | A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma |
| Q41939405 | A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab |
| Q89099332 | A Systemic Lupus Erythematosus Patient With Febrile Neutropenia Developing After Intraocular Administration of Bevacizumab |
| Q36163040 | A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. |
| Q41965001 | A pre-operative nomogram for decision making in oncological surgical emergencies |
| Q54415533 | A prognostic indicator of survival in metastatic colorectal cancer patients in the era of molecular-targeted agents: the modified Glasgow Prognostic Score. |
| Q21090878 | A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard |
| Q30301267 | A synthesis of clinical recommendations and primary research for survivors of prostate or breast cancer |
| Q35144007 | Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis |
| Q26822395 | Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups |
| Q47815963 | Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial |
| Q36243664 | Aflibercept in pediatric solid tumors: moving beyond the trap |
| Q31152878 | An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients |
| Q35380959 | Angiogenesis and melanoma - from basic science to clinical trials. |
| Q83690378 | Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream |
| Q40507543 | Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients |
| Q34554380 | Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future |
| Q37983389 | Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities |
| Q42143173 | Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas |
| Q37706985 | Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism |
| Q99585277 | Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials |
| Q38085569 | Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases |
| Q33930609 | Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q38111265 | Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Q34593475 | Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis |
| Q28076188 | Bevacizumab in ovarian cancer: A critical review of phase III studies |
| Q33396369 | Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach |
| Q46283167 | Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. |
| Q27027498 | Bevacizumab treatment for advanced breast cancer |
| Q43228695 | Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN. |
| Q84985820 | Bp5250 inhibits vascular endothelial growth factor-induced angiogenesis and HIF-1α expression on endothelial cells |
| Q43135873 | Breaking down the evidence for bevacizumab in ovarian cancer |
| Q49722419 | Cancer patients in operative intensive care medicine |
| Q38371293 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients |
| Q36751861 | Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives |
| Q37960873 | Cardiovascular toxicity of anti-angiogenic drugs |
| Q37967508 | Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology |
| Q35599819 | Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. |
| Q38055499 | Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas |
| Q48760231 | Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit? |
| Q34105997 | Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
| Q38261105 | Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. |
| Q35117298 | Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. |
| Q27023510 | Contemporary use of bevacizumab in ovarian cancer |
| Q37869151 | Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas |
| Q26823757 | Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin) |
| Q42001807 | Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuita |
| Q35650268 | Current intravitreal pharmacologic therapies for diabetic macular edema |
| Q37947681 | Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments |
| Q47722523 | Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. |
| Q34208140 | Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment |
| Q51150156 | Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. |
| Q35584395 | Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis |
| Q31060162 | Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature |
| Q39029184 | Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma |
| Q39340696 | Emerging growth factor receptor antagonists for the treatment of advanced melanoma |
| Q30657829 | First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. |
| Q37909171 | First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study |
| Q47673133 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications |
| Q48150990 | Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer. |
| Q38832795 | Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. |
| Q35833194 | HSPA12B: a novel facilitator of lung tumor growth |
| Q26826505 | Health economic aspects of breast cancer treatment: the compulsory health insurances' view |
| Q36644408 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies |
| Q37980338 | Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis |
| Q37669073 | Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey |
| Q36048205 | Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis |
| Q92802225 | Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials |
| Q38005357 | Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers |
| Q34778631 | Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis |
| Q88636568 | Intestinal perforation after regorafenib usage |
| Q53479365 | Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies. |
| Q38704738 | Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis. |
| Q24632703 | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer |
| Q39358771 | Key points to optimizing management and research on cancer-associated thrombosis. |
| Q26852509 | Lessons learned from the bevacizumab experience |
| Q36963353 | Low-event-rate meta-analyses of clinical trials: implementing good practices |
| Q35061280 | Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials |
| Q62581024 | Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study |
| Q38570532 | Management of pulmonary toxicity associated with targeted anticancer therapies |
| Q35155460 | Management options in triple-negative breast cancer |
| Q35038600 | Mechanism of kidney injury caused by bevacizumab in rats |
| Q91388651 | Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers |
| Q36174910 | Molecular targeted approaches for treatment of pancreatic cancer. |
| Q38153444 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer |
| Q34951074 | Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab |
| Q38071374 | Monoclonal antibodies in oncology therapeutics: present and future indications |
| Q92381936 | Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours |
| Q53158899 | Nerve/Glial Antigen 2: A Novel Target for Anti-Tumor Therapy in Colorectal Cancer. |
| Q33564645 | New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management |
| Q84704956 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC) |
| Q30472751 | Oncologic Angiogenesis Imaging in the clinic---how and why. |
| Q38154665 | Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer |
| Q37986561 | Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? |
| Q36213475 | Personalized cancer medicine--advances and socio-economic challenges |
| Q28083801 | Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives |
| Q36864032 | Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer |
| Q85738014 | Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer |
| Q37081896 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma |
| Q33408836 | Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer |
| Q36921895 | Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer |
| Q37606640 | Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. |
| Q38489591 | Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy |
| Q35909225 | Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts |
| Q40304799 | Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. |
| Q38312076 | Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients |
| Q59616684 | Progress against solid tumors in danger: the metastatic breast cancer example |
| Q36095223 | Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? |
| Q28482364 | Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear |
| Q38977239 | RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. |
| Q26779221 | Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications |
| Q26749541 | Ramucirumab: Boon or bane |
| Q47640245 | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
| Q38091030 | Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment |
| Q37094898 | Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q42158334 | RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA. |
| Q26783779 | Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis |
| Q92772956 | Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis |
| Q52871581 | Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. |
| Q64090553 | Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis |
| Q64885829 | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. |
| Q39258192 | Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†. |
| Q37956392 | Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials |
| Q33949406 | Risks and benefits with bevacizumab: evidence and clinical implications |
| Q38847242 | Safety and complications of intravitreal injections performed in an Asian population in Singapore |
| Q36640122 | Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study |
| Q37903602 | Safety of bevacizumab in patients with metastatic breast cancer |
| Q36993476 | Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience |
| Q87568566 | Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab |
| Q29248727 | Switching off malignant mesothelioma: exploiting the hypoxic microenvironment |
| Q38062459 | Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer |
| Q38225636 | Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer |
| Q24193614 | Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration |
| Q24195003 | Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration |
| Q34286194 | Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas |
| Q37743048 | Targeted therapies in breast cancer: New challenges to fight against resistance |
| Q83751809 | Targeted therapies: disappointing outcomes for anti-VEGF therapy |
| Q84069773 | Targeted therapies: peaking beneath the surface of recent bevacizumab trials |
| Q35184806 | Targeting the tumor microenvironment: focus on angiogenesis |
| Q49056479 | Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise? |
| Q38811461 | The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside |
| Q35626139 | The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells |
| Q55083555 | The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. |
| Q49718931 | The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis. |
| Q34115840 | The expanding role of vascular endothelial growth factor inhibitors in ophthalmology |
| Q26775232 | The fate of chemoresistance in triple negative breast cancer (TNBC) |
| Q26824086 | The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review |
| Q49795317 | The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective |
| Q26851314 | The microenvironment in breast cancer progression: biology and implications for treatment |
| Q48147528 | The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism |
| Q37662274 | The use of and adherence to CTCAE v3.0 in cancer clinical trial publications |
| Q39614989 | The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy |
| Q35908498 | Therapeutic antibodies against cancer |
| Q35419411 | Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab |
| Q35596957 | Toward a Cancer Drug of Fungal Origin |
| Q36804502 | Toxicity of bevacizumab in combination with chemotherapy in older patients |
| Q54386535 | Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. |
| Q33699582 | Treatment-related mortality with everolimus in cancer patients. |
| Q33631305 | Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis |
| Q37887823 | Trials of bevacizumab in breast cancer--a safety review |
| Q36530636 | Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. |
| Q35109936 | Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents |
| Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
| Q33408049 | Understanding, recognizing, and managing toxicities of targeted anticancer therapies |
| Q36067717 | Use and misuse of common terminology criteria for adverse events in cancer clinical trials |
| Q48342585 | Use of Antihypertensive Drugs in Neoplastic Patients |
| Q40898144 | Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report |
| Q35233993 | Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application |
| Q37345045 | VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. |
| Q37309920 | Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma |
| Q24202199 | Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer |
| Q35642338 | Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer |
| Q51819677 | Zielgerichtete gynäko-onkologische Therapien – häufige Nebenwirkungen und deren Management. |
| Q91911514 | [Cancer patients in operative intensive care medicine] |
| Q86054460 | [Ranibizumab versus bevacizumab. Pharmacological considerations] |
Search more.